Announcements
Announcement of acquisition of preferred shares of Odeon Therapeutics (Cayman) Limited
1.Name and nature of the underlying assets (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield, etc.): Preferred shares of Odeon Therapeutics (Cayman) …
OBI Enters License Agreement with Odeon for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau
1.Date of occurrence of the event:2022/02/22 2.Counterparty to the contract or commitment: Odeon Therapeutics (Hong Kong) Limited (hereinafter referred to as “ Odeon”) 3.Relationship with the Company: None 4.Starting and …
OBI is invited to attend the“ QIC Healthcare Forum” (Investor meeting on air) held by QIC
1.Date of institutional investor conference: 2022/02/16~2022/02/18 2.Time of institutional investor conference: 14:40 3.Location of institutional investor conference: online conference 4.Outline of institutional investor conference: OBI is invited to attend the“ …
Announcement of issue price and banks designated to collect and deposit the proceeds
1.Date of the board of directors resolution or decision by the Company for record date: 2022/02/11 2.Whether to adopt shelf registration (Yes/No): No 3.Effective registration date approved by competent authority: …
The Active Cancer Immunotherapy OBI-822, has been granted by ANVISA of Brazil to proceed to Phase III Clinical Trial
1.Date of occurrence of the event: 2022/02/09 2.New drug name or code: Active Cancer Immunotherapy OBI-822 (Adagloxad Simolenin) 3.Indication: OBI-822 is a therapeutic cancer vaccine classified as active cancer immunotherapy. …
Supplementary statements on news article
1.Date of occurrence of the event: 2022/02/09 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”): Head office 4.Reciprocal shareholding ratios: Not applicable 5.Name …
Announcement of preclinical animal study results of OBI’s COVID-19 vaccine
1.Date of occurrence of the event: 2022/02/08 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”): Head office 4.Reciprocal shareholding ratios: Not applicable 5.Cause …
The Active Cancer Immunotherapy OBI-822, has been granted by URPL of Poland to proceed to Phase III Clinical Trial
1. Date of occurrence of the event: 2022/01/28 2. New drug name or code: Active Cancer Immunotherapy OBI-822 (Adagloxad Simolenin) 3. Indication: OBI-822 is a therapeutic cancer vaccine classified as …
Announcement of reference date of 2022 cash capital increase and share subscription
1.Date of the resolution by the board of directors or decision by the Company: 2022/01/25 2.Number of shares issued: 30,000,000 common shares 3.Par Value per share: 10 NTD 4.Total monetary …
The Active Cancer Immunotherapy OBI-822, has been granted by AEMPS of Spain to proceed to Phase III Clinical Trial
1.Date of occurrence of the event: 2022/01/25 2.New drug name or code: Active Cancer Immunotherapy OBI-822 (Adagloxad Simolenin) 3.Indication: OBI-822 is a therapeutic cancer vaccine classified as active cancer immunotherapy. …